Health & Fitness
Thu, February 24, 2011Wed, February 23, 2011Tue, February 22, 2011Mon, February 21, 2011Sun, February 20, 2011Fri, February 18, 2011Thu, February 17, 2011Wed, February 16, 2011Tue, February 15, 2011Mon, February 14, 2011Fri, February 11, 2011Thu, February 10, 2011Wed, February 9, 2011Tue, February 8, 2011Nuclear Regulatory Commission Approves Radioactive Materials License for Positron Facility
Published in Health and Fitness on Wednesday, February 16th 2011 at 6:25 GMT by Market Wire
INDIANAPOLIS--([ BUSINESS WIRE ])--Positron Corporation (OTC BB:POSC) a molecular imaging company focused on nuclear cardiology, announced today that the Nuclear Regulatory Commission (NRC) has approved an amendment to their existing Indiana license for handling radioactive materials to include Positrona™s Crown Point, Indiana facility.
"A radioactive material handling license at this facility is a critical step that allows Positron to expand its business through the development and manufacturing of new technologies, medical devices and radiopharmaceuticals, thereby further solidifying our position in the marketplace"
aFrom inception, our Crown Point facility was designed specifically to facilitate Positrona™s growth plans into radiopharmaceuticals. The NRC license allows us to bring this facility to its fully functional and operational stage, and to immediately move into the development, production and sales of radiochemical compounds, with a planned near-term expansion into radiopharmaceuticals for oncology and cardiology.
aA radioactive material handling license at this facility is a critical step that allows Positron to expand its business through the development and manufacturing of new technologies, medical devices and radiopharmaceuticals, thereby further solidifying our position in the marketplace,a said Scott Stiffler, Positrona™s vice president of pharmaceuticals.
About Positron: Positron is a molecular imaging company focused on Nuclear Cardiology. Positron Corporation, a pioneer in positron emission tomography for more than 25 years provides unique solutions for the nuclear medicine community through the production and distribution of proprietary molecular imaging systems and radiopharmaceutical products. More information about Positron is available at [ www.positron.com ].
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
